The correct answer is A. True.
A post-hoc subgroup analysis of the RE-LY trial, which randomized patients to warfarin or dabigatran, analyzed the subset of patients who were on concomitant antiplatelet agents. The study concluded that use of antiplatelet agents with any oral anticoagulant increased risk of bleeding and use of two antiplatelet agents increased risk of bleeding more than a single antiplatelet agent. It also found that the absolute bleeding risk was lowest on dabigatran 110 mg compared to dabigatran 150 mg or warfarin.
3. According to the RE-DUAL PCI randomized clinical trial, which of the following regimens among patients with AF who have undergone PCI has the lowest rate of bleeding?
A. Aspirin plus a P2Y12 inhibitor (clopidogrel or ticagrelor) plus warfarin.
B. Dabigatran 110 mg plus P2Y12 inhibitor (clopidogrel or ticagrelor).
C. Dabigatran 150 mg plus P2Y12 inhibitor (clopidogrel or ticagrelor).
D. Aspirin plus rivaroxaban.